Pharmacokinetics after administration of an injectable experimental long-acting parenteral formulation of doxycycline hyclate in goats

American Journal of Veterinary Research

Volumn 69, Issue 8, 2008, Pages 1085-1090

  Vargas, Dinorah ^a   Gutierrez, Lilia ^a   Juárez, Ivan ^a   Gonzalez, Francisco ^a   Sumano, Héctor ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE HYCLATE;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; GOAT; LONG ACTING DRUG FORMULATION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALIA; BACTERIA (MICROORGANISMS); CAPRA HIRCUS;

EID: 49749114846     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.69.8.1085     Document Type: Article

References (36)

1. Suzuka I, Kaji H, Kaji A. Binding of specific sRNA to 30S ribosomal subunits: effects of 50S ribosomal subunits. Proc Natl Acad Sci U S A 1966;55:1483-1486.
2. Riond JL, Riviere JE. Doxycycline binding to plasma albumin of several species. J Vet Pharmacol Ther 1989;12:253-260.
3. Shaw DH, Rubin SI. Pharmacologic activity of doxycycline. J Am Vet Med Assoc 1986;189:808-810.
4. Schach von Wittenau M, Twomey TM. The disposition of doxycycline by man and dog. Chemotherapy 1971;16:217-228.
5. Whelton A, Schach Von Wittenau M, Twomey TM, et al. Doxycycline pharmacokinetics in the absence of renal function. Kidney Int 1974;5:365-371.
6. Baumueller A, Madsen PO. Secretion of various antimicrobial substances in dogs with experimental bacterial prostatitis. Urol Res 1977;5:215-218.
7. Ole-Mapenay IM, Mitema ES, Mathio TE. Aspects of pharmacokinetics of doxycycline given to healthy and pneumonic east African dwarf goats by intramuscular injection. Vet Res Commun 1997;21:453-462.
8. Chopra I, Howe TGB, Linton KB, et al. The tetracyclines: prospects at the beginning of the 1980s. J Antimicrob Chemother 1981;8:5-21.
9. Cunha BA, Sibley CM, Ristuccia AM. Doxycycline. Ther Drug Monit 1982;4:115-135.
10. Prescott JF. Tetracyclines. In: Prescott JF, BaggoL DJ, Walker RD eds. Antimicrobial therapy in veterinary medicine. 3rd ed. Ames, Iowa: Iowa State University Press, 2000;275-289.
11. Craig WA. Pharmacokinetic-pharmacodynamic parameters: rationale for antibiotic use in mice and men. Clin Infect Dis 1998;26:1-12.
12. Bekers O, Uijtendaal EV, Beijnen JH, et al. Cyclodextrins in the pharmaceutical field. Drug Dev Ind Pharm 1991;17:1503-1549.
13. Bennett JV, Brodie JL, Benner EJ, et al. Simplified, accurate method for antibiotic assay of clinical specimens. Appl Microbiol 1966;14:170-177.
14. Welling PG. Drug absorption, distribution, metabolism, and excretion. In: Welling PG, ed. Pharmacokinetics, processes, mathematics and applications. ACS professional reference book. 2nd ed. Washington, DC: American Chemical Society, 1997;11-34.
15. Kabanov AV, Batrakova EV, Melik-Nubarov NS, et al. A new class of drug carriers: micelles of poly (oxyethylene)- poly (oxypropylene)- poly (oxyethylene) block copolymers as microcontainers for drug targeting from blood in brain. J Control Release 1992;22:141-158.
16. Tarr BD, Yalkowsky SH. A new parenteral vehicle for the administration of some poorly water soluble anti-cancer drugs. J Parenter Sci Technol 1987;41:31-33.
17. Schmolka IR. Poloxamers in the pharmaceutical industry. In: Tarcha PJ, ed. Polymers of controlled drug delivery. Boca Raton, Fla: CRC Press, 1991;189-214.
18. Yoshida A, Yamamoto M, Itoh T, eL al. Utility of 2-hydroxypropyl-beta-cyclodextrin in an intramuscular injectable preparation of nimodipine. Chem Pharm Bull (Tokyo) 1990; 38:176-179.
19. Uekama K, Hirayama F, Irie T. Cyclodextrin drug carrier systems. Chem Rev 1998;98:2045-2076.
20. Szejtli J. Molecular entrapment and release properties of drugs by cyclodextrins and congeners. In: Smallen E Ball L, eds. Controlled drug bioavailability. New York: John Wiley & Sons, 1985;365-421.
21. Abd El-Aty AM, Goudaha A, Zhou HH. Pharmacokinetics of doxycycline after administration as a single intravenous bolus and intramuscular doses to non-lactating Egyptian goats. Pharmacol Res 2004;49:487-491.
22. Ole-Mapenay IM, Mitema ES. Some pharmacokinetic parameters of doxycycline in east African goats after intramuscular administration of a long acting formula. Vet Res Commun 1995;19:425-432.
23. Gilbert JC, Richardson JL, Davies MC, et al. The effect of solutes and polymers on the gelation properties of pluronic F127 solutions for controlled drug delivery. J Control Release 1987;5:113-118.
24. Lawrence MJ. Surfactant systems microemulsions and vesicles as vehicles for drug delivery. Eur J Drug Metab Pharmacokinet 1994;19:257-259.
25. Inskeep PB, Darrington RT. Utilization of biopharmaceutical and pharmacokinetic principles in the development of veterinary controlled release drug delivery systems. In: Rathbone MJ, Gumy R, eds. Controlled release veterinary drug delivery. Amsterdam: Elsevier Science BV, 2000;1-15.
26. Toutain PL, Bousquet-Mélou A. Bioavailability and its assessment. J Vet Pharmacol Ther 2004;27:455-466.
27. Aronson AL. Pharmacotherapeutics of the newer tetracyclines. J Am Vet Med Assoc 1980;176:1061-1068.
28. Riond JL, Riviere JE. Pharmacology and toxicology of doxycycline. J Vet Hum Toxicol 1988;30:431-443.
29. Brook I, Elliott TB, Pryor HI, et al. In vitro resistance of Bacillus anthracis Sterne to doxycychne, macrolides and quinolones. Int J Antimicrob Agents 2001;18:559-562.
30. Hospenthal DR, Murray CK. In vitro susceptibilities of seven Leptospira species to traditional and newer antibiotics. Antimicrob Agents Chemother 2003;47:2646-2648.
31. Guerin-Faublee V, Flandrois JP, Broye E, et al. Actmomyces pyogenes: susceptibility of 103 clinical animal isolates to 22 antimicrobial agents. Vet Res 1993;24:251-259.
32. Yoshimura H, Ishimura M, Endoh YS, et al. Antimicrobial susceptibility of Pasteurella multocida isolated from cattle and pigs. J Vet Med 2001;48:555-560.
33. Cunha BA, Domenico P, Cunha CB. Pharmacodynamics of doxycycline. Clin Microbiol Infect 2000;6:270-273.
34. Notari RE. Principles of pharmacokinetics: dosage regimen. In: Notari RE, ed. Biopharmaceutics and clinical pharmacokineties: an introduction. 4th ed. New York: Marcel-Dekker, 1987;45-212.
35. Baños JE, Ferré AM. Principios de farmacocinética clínica. In: Baños JE, Ferré AM, eds. Principios de farmacología clínica. Bases científicas de la utilización de medicamentos. Amsterdam: Elsevier-Masson, 2002; 31-56.
36. Ailani RK, Agastya G, Ailani RK, et al. Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia. Arch Intern Med 1999;159:266-270.